CDKN2A and cancer: Loss of CDKN2A is known to correlate with poor outcome in ccRCC, PRCC, and other cancer types, but this demonstrates that it is a universal feature of RCC and is potentially targetable with CDK4/6 inhibitors that target the downstream effects of p16 loss (Hamilton and Infante, 2016).